The leading gene editing company CRISPR Therapeutics (CRSP) is looking better to technically oriented traders. Let's take a look.
In this daily bar chart of CRSP, below, we can see that following a downtrend that prices have turned sideways since January. Dips towards and into the $50-$40 area have been bought. The 50-day moving average line has bottomed out and now prices are trading above this indicator. The still declining 200-day moving average line was tested from below in June and we could see prices close above the 200-day line in July.